Abstract
A better understanding of the molecular pathways regulating the bone remodeling process should help in the development of new antiresorptive regulators and anabolic regulators, that is, regulators of bone resorption and of bone formation. Understanding the mechanisms by which parathyroid hormone (PTH) influences bone formation and how it switches from anabolic to catabolic action is important for treating osteoporosis (Poole and Reeve in Curr Opin Pharmacol 5:612–617, 2005). In this paper we describe a mathematical model of bone remodeling that incorporates, extends, and integrates several models of particular aspects of this biochemical system (Cabal et al. in J Bone Miner Res 28(8):1830–1836, 2013; Lemaire et al. in J Theor Biol 229:293–309, 2004; Peterson and Riggs in Bone 46:49–63, 2010; Raposo et al. in J Clin Endocrinol Metab 87(9):4330–4340, 2002; Ross et al. in J Disc Cont Dyn Sys Series B 17(6):2185–2200, 2012). We plan to use this model as a bone homeostasis platform to develop anabolic and antiresorptive compounds. The model will allow us to test hypotheses about the dynamics of compounds and to test the potential benefits of combination therapies. At the core of the model is the idealized account of osteoclast and osteoblast signaling given by Lemaire et al. (J Theor Biol 229:293–309, 2004). We have relaxed some of their assumptions about the roles of osteoprotegerin, transforming growth factor \(\upbeta \), and receptor activator of nuclear factor \(\upkappa \)B ligand; we have devised more detailed models of the interactions of these species. We have incorporated a model of the effect of calcium sensing receptor antagonists on remodeling (Cabal et al. in J Bone Miner Res 28(8):1830–1836, 2013). We have also incorporated a basic model of the effects of vitamin D on calcium homeostasis. We have included a simple model of the mechanism proposed by Bellido et al. (2003), Ross et al. (J Disc Cont Dyn Sys Series B 17(6):2185–2200, 2012), of the influence of PTH on osteoblast apoptosis, a mechanism that accounts for the anabolic response to pulsatile PTH administration. Finally, we have devised a simple model of the administration and effects of bisphosphonates. The biomarkers in the model are procollagen type 1 amino-terminal propeptide and C-terminal telopeptide. Bone mineral density is the model’s principal endpoint.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11538-016-0229-2/MediaObjects/11538_2016_229_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11538-016-0229-2/MediaObjects/11538_2016_229_Fig2_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11538-016-0229-2/MediaObjects/11538_2016_229_Fig3_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11538-016-0229-2/MediaObjects/11538_2016_229_Fig4_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11538-016-0229-2/MediaObjects/11538_2016_229_Fig5_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11538-016-0229-2/MediaObjects/11538_2016_229_Fig6_HTML.gif)
Similar content being viewed by others
References
Aslan D, Dahl Andersen M, Bjerring Gede L, De Franka TK, Jorgensen SR, Schwarz P, Rye Jorgensen N (2012) Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans. Scand J Clin Lab Invest 72:14–22
Aubin JE, Bonnelye E (2000) Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 11:905–913
Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein PS, O’Brien CA, Manolagas SC, Jilka RL (2003) Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. J Biol Chem 278(50):50259–50272
Bonewald LF, Dallas SL (1994) Role of active and latent transforming growth factor beta in bone formation. J Cell Biochem 55:350–357
Cabal A, Mehta K, Ross DS, Shrestha R, Comisar W, Denker A (2013) A semi-mechanistic model of the time-course of release of PTH into plasma following administration of the calcilytic JTT-305/MK-5442 in humans. J Bone Miner Res 28(8):1830–1836
Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83(9):1032–1045
Eriksen EF (2010) Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord 11:219–227
Filaroff E, Derynck R (1998) Bone remodeling: a signalling system for osteoclast regulation. Curr Biol 8:R679–R682
Fox SW, Lovibond AC (2005) Current insights into the role of transforming growth factor-beta in bone resorption. Mol Cell Endocrinol 243:19–26
Günther T, Schinke T (2000) Mouse genetics have uncovered new paradigms in bone biology. Trends Endocrin Met 11(5):189–193
Halladay DL, Miles RR, Thirunavukkarasu K, Chandrasekhar S, Martin TJ, Onyia JE (2002) Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1–38 of osteoprotegerin gene expression. J Cell Biochem 84:1–11
Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15(1):2–12
Houde N, Chamoux E, Bisson M, Roux S (2009) Transforming growth factor-b1 (TGF-b1) induces human osteoclast apoptosis by up-regulating Bim. J Biol Chem 284(35):23397–23404
Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman DG, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10(10):1478–1487
Janssens K, ten Dijke P, Janssens S, van Hul W (2005) Transforming growth factor-b1 to the bone. Endocr Rev 26:743–774
Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050–5055
Komorova S, Smith RJ, Dixon SJ, Sims SM, Wahle LM (2003) Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling. Bone 33:206–215
Lemaire V, Tobin FL, Greller LD, Cho CR, Suva LJ (2004) Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. J Theor Biol 229:293–309
Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE (2001) Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142(9):4047–4054
Marathe A, Peterson MC, Mager DE (2008) Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther 326:555–562
Nishimura R (2009) A novel role for TGF-\(\beta \)1 in bone remodeling. IBMS Bonekey 6(11):434–438
Peterson M, Riggs M (2010) A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone 46:49–63
Pleiner-Duxneuner J, Zwettler E, Paschalis E, Roschger P, Nell-Duxneuner V, Klaushofer K (2009) Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int 84(3):159–170. Erratum in: Calcif Tissue Int 85(5):463
Poole KES, Reeve J (2005) Parathyroid hormone–a bone anabolic and catabolic agent. Curr Opin Pharmacol 5:612–617
Raposo JF, Sobrinho LG, Ferreira HG (2002) A minimal mathematical model of calcium homeostasis. J Clin Endocrinol Metab 87(9):4330–4340
Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L (2008) Plasma 1,25(OH)2D levels decrease in postmenopausal women with hypovitaminosis. Eur J Endocrinol 158:571–576
Roodman GD (1999) Cell biology of the osteoclast. Exp Hematol 27:1229–1241
Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222s–6230s
Ross DS, Battista C, Cabal A, Mehta K (2012) Dynamics of cell signaling and PTH treatments for osteoporosis. J Disc Cont Dyn Sys Series B 17(6):2185–2200
Ruffoni D, Fratzl P, Roschger P, Klaushofer K, Weinkamer R (2007) The bone mineralization density distribution as a fingerprint of the mineralization process. Bone 40:1308–1319
Seeman E, Delmas PD (2001) Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab 12:281–283
Shrestha RP, Hollot CV, Chipkin SR, Schmitt CP, Chait Y (2010) A mathematical model of acute response of parathyroid hormone to changes in plasma ionized calcium in normal humans. Math Biosci 226:46–57
Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F, Baulieu EE (2001) Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 86:3086–3090
Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289(5484):1504–1508
Acknowledgements
This study was funded by Merck & Co., Inc., Kenilworth, NJ. The authors would like to thank Boyd B. Scott Ph.D., Sheila Erespe MS, and Jennifer Pawlowski MS of Merck & Co., Inc., Kenilworth, NJ, for their assistance in the preparation and submission of this manuscript.
Funding This study was funded by Merck & Co., Inc., Kenilworth, NJ.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ross, D.S., Mehta, K. & Cabal, A. Mathematical Model of Bone Remodeling Captures the Antiresorptive and Anabolic Actions of Various Therapies. Bull Math Biol 79, 117–142 (2017). https://doi.org/10.1007/s11538-016-0229-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11538-016-0229-2